Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 6 | 4 |
| List of Tables | 8 | 1 |
| List of Figures | 9 | 1 |
| Ophthalmology Therapeutics in Major Markets Introduction | 10 | 11 |
| Dry Eye Syndrome | 10 | 1 |
| Classification | 10 | 1 |
| Symptoms | 10 | 1 |
| Etiology | 10 | 1 |
| Pathophysiology | 11 | 1 |
| Diagnosis | 12 | 1 |
| Epidemiology | 13 | 1 |
| Prognosis | 14 | 1 |
| Treatment Options | 14 | 1 |
| Glaucoma | 15 | 1 |
| Classification | 15 | 1 |
| Symptoms | 16 | 1 |
| Etiology | 16 | 1 |
| Pathophysiology | 17 | 1 |
| Diagnosis | 17 | 1 |
| Tonometry | 17 | 1 |
| Pachymetry | 18 | 1 |
| Gonioscopy | 18 | 1 |
| Ophthalmoscopy | 18 | 1 |
| Visual Field Testing | 18 | 1 |
| Epidemiology | 18 | 1 |
| Prognosis | 19 | 1 |
| Treatment Options | 19 | 1 |
| Pharmacological Treatment | 19 | 1 |
| Laser Surgery | 20 | 1 |
| Traditional Surgery | 20 | 1 |
| Ophthalmology Therapeutics in Major Markets Marketed Products (Global) | 21 | 9 |
| Dry Eye Syndrome | 21 | 1 |
| Glaucoma | 21 | 1 |
| Key Marketed Products | 22 | 1 |
| Restasis | 22 | 1 |
| Systane | 23 | 1 |
| Diquas | 24 | 1 |
| Mucosta | 25 | 1 |
| Hyalein | 26 | 1 |
| Lumigan | 27 | 1 |
| Alphagan/Alphagan P | 28 | 1 |
| Simbrinza | 29 | 1 |
| Ophthalmology Therapeutics in Major Markets Pipeline Analysis | 30 | 13 |
| Dry Eye Syndrome Pipeline | 30 | 1 |
| Overall Pipeline | 30 | 2 |
| Pipeline Analysis by Molecule Type | 32 | 2 |
| Pipeline Analysis by Mechanism of Action | 34 | 2 |
| Glaucoma Pipeline | 36 | 1 |
| Overall Pipeline | 36 | 2 |
| Pipeline Analysis by Molecule Type | 38 | 1 |
| Pipeline Analysis by Mechanism of Action | 39 | 2 |
| Promising Drug Candidates in the Pipeline | 41 | 1 |
| CF-101 | 41 | 1 |
| MIM-D3 | 41 | 1 |
| SAR-1118 | 41 | 1 |
| DE-111 | 42 | 1 |
| Ophthalmology Therapeutics in Major Markets Market Forecast to 2019 | 43 | 12 |
| Major Markets | 43 | 1 |
| Treatment Usage Patterns | 43 | 1 |
| Annual Cost of Therapy | 43 | 1 |
| Market Size | 43 | 2 |
| The US | 45 | 1 |
| Treatment Usage Patterns | 45 | 1 |
| Annual Cost of Therapy | 45 | 1 |
| Market Size | 45 | 2 |
| Top Five European Countries | 47 | 1 |
| Treatment Usage Patterns | 47 | 1 |
| Annual Cost of Therapy | 47 | 1 |
| Market Size | 47 | 2 |
| Canada | 49 | 1 |
| Treatment Usage Patterns | 49 | 1 |
| Annual Cost of Therapy | 49 | 1 |
| Market Size | 49 | 2 |
| Japan | 51 | 1 |
| Treatment Usage Patterns | 51 | 1 |
| Annual Cost of Therapy | 51 | 1 |
| Market Size | 51 | 2 |
| Drivers and Barriers | 53 | 1 |
| Drivers | 53 | 1 |
| Increase in Prevalence of Dry Eye Syndrome | 53 | 1 |
| Launch of New Prescription Products | 53 | 1 |
| Barriers | 53 | 1 |
| Lack of Awareness and Compliance | 53 | 1 |
| Patent Expiries of Major Marketed Drugs | 53 | 2 |
| Ophthalmology Therapeutics in Major Markets Deals and Strategic Consolidations (Global) | 55 | 6 |
| Deals Analysis | 55 | 2 |
| Major Co-Development Deals | 57 | 1 |
| NicOx Signs Research Agreement with Pfizer | 58 | 1 |
| Acucela Enters into Co-development Agreement with Otsuka Pharma for Rebamipide | 58 | 1 |
| Akorn Enters into Agreement with Azad Pharma | 58 | 1 |
| Major Licensing Deals | 59 | 1 |
| NicOx Enters into Worldwide Licensing Agreement with Bausch &Lomb | 60 | 1 |
| Quark Pharma Amends Licensing Agreement with Pfizer for PF-655 | 60 | 1 |
| Asterand Enters into Licensing Agreement with Allergan | 60 | 1 |
| Ophthalmology Therapeutics in Major Markets Appendix | 61 | 20 |
| All Pipeline Drugs by Phase | 61 | 6 |
| Discovery | 61 | 1 |
| Preclinical | 61 | 2 |
| IND/CTA-filed | 63 | 1 |
| Phase I | 63 | 1 |
| Phase II | 64 | 1 |
| Phase III | 65 | 1 |
| Pre-registration | 65 | 1 |
| Undisclosed | 66 | 1 |
| Market Forecasts to 2019 | 66 | 7 |
| Major Markets | 66 | 1 |
| Dry Eye Syndrome | 66 | 1 |
| Glaucoma | 66 | 1 |
| The US | 67 | 1 |
| Dry Eye Syndrome | 67 | 1 |
| Glaucoma | 67 | 1 |
| The UK | 67 | 1 |
| Dry Eye Syndrome | 67 | 1 |
| Glaucoma | 68 | 1 |
| France | 68 | 1 |
| Dry Eye Syndrome | 68 | 1 |
| Glaucoma | 68 | 1 |
| Germany | 69 | 1 |
| Dry Eye Syndrome | 69 | 1 |
| Glaucoma | 69 | 1 |
| Italy | 69 | 1 |
| Dry Eye Syndrome | 69 | 1 |
| Glaucoma | 70 | 1 |
| Spain | 70 | 1 |
| Dry Eye Syndrome | 70 | 1 |
| Glaucoma | 70 | 1 |
| Canada | 71 | 1 |
| Dry Eye Syndrome | 71 | 1 |
| Glaucoma | 71 | 1 |
| Japan | 71 | 1 |
| Dry Eye Syndrome | 71 | 1 |
| Glaucoma | 72 | 1 |
| Market Definitions | 72 | 1 |
| Abbreviations | 72 | 2 |
| Sources | 74 | 1 |
| Research Methodology | 75 | 6 |
| Coverage | 76 | 1 |
| Secondary Research | 76 | 1 |
| Primary Research | 76 | 1 |
| Therapeutic Landscape | 77 | 2 |
| Market Size by Geography | 79 | 1 |
| Geographical Landscape | 80 | 1 |
| Pipeline Analysis | 80 | 1 |
| Expert Panel Validation | 80 | 1 |
| Contact Us | 80 | 1 |
| Disclaimer | 80 | 1 |